Dr. Bekaii-Saab on Adjuvant Therapy in Pancreatic Cancer

Video

In Partnership With:

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses adjuvant therapy in pancreatic cancer.

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses adjuvant therapy in pancreatic cancer.

Physicians know that about 10% to 15% of patients will present with advanced nonmetastatic pancreas cancer in the adjuvant setting. These patients have either resectable, borderline resectable, or locally advanced nonmetastatic disease, says Bekaii-Saab. Most, if not all, of those patients whose tumors are resectable will end up in surgery. About half of patients with borderline resectable tumors will go to surgery, and about 10% to 15% of patients with locally advanced disease will go to surgery.

Based on the ESPAC-4 study, physicians know that capecitabine and gemcitabine should be the standard for patients with resectable disease. In the United States, physicians should probably use lower doses of capecitabine than used in the ESPAC-4 trial by the Europeans because of the history of capecitabine in the United States versus in Europe.

Radiation does not have a defined role yet, explains Bekaii-Saab. There are studies that have reported positive findings, negative findings, and in between. At this point in time, radiation does not seem to have a role, although it is still being explored in the adjuvant setting. Ultimately, patients with very clear resectable disease will receive adjuvant therapy.

Related Videos
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD